EAACI biologicals guidelines-omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old

Agache, Ioana; Akdis, Cezmi A.; Akdis, Mubeccel; Brockow, Knut; Chivato, Tomas; Del Giacco, Stefano; Eiwegger, Thomas; Eyerich, Kilian; Giménez Arnau, Anna Maria; Gutermuth, Jan; Guttman-Yassky, Emma; Maurer, Marcus; Ogg, Graham; Ong, Peck Y.; O'Mahony, Liam; Schwarze, Jürgen; Warner, Amena; Werfel, Thomas; Palomares, Oscar; Jutel, Marek

doi:http://dx.doi.org/10.1111/all.15030

EAACI biologicals guidelines-omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old

Citation

Agache I, Akdis CA, Akdis M, Brockow K, Chivato T, Del Giacco S, et al. EAACI biologicals guidelines-omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. Allergy. 2022 Jan; 77(1): 17-38. DOI: 10.1111/all.15030

Abstract

Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.